The present disclosure provides glycosyl hydrolases (e.g., OGA) comprising a ligand-dependent intein. The present disclosure also provides pharmaceutical compositions comprising the glycosyl hydrolases disclosed herein, as well as polynucleotides, vectors, cells, and kits. Methods of using the disclosed intein-containing glycosyl hydrolases are also provided herein, including methods of deglycosylating a target protein. Methods of treating a glycosylation-associated disease in a subject, as well as methods of sensitizing a cell to a desirable therapeutic outcome, are also provided herein.

The present application relates to a disaccharide linker, a disaccharide-small molecule drug conjugate and a sugar chain fixed-point antibody-drug conjugate, a preparation method and the use thereof. The structure of the disaccharide linker is as shown in the following formula I. The present invention provides a new-type fixed-point and quantitative antibody-drug conjugate form, and the stability and cytotoxicity of the antibody-drug conjugate are improved.

##STR00001##

Described herein are biological devices and extracts useful for detecting Alzheimer's disease and/or concussions. The biological devices include microbial cells transformed with a DNA construct containing genes for producing -amyloid precursor protein, microtubule associated protein tau, adipose triglyceride lipase, acyl-CoA dehydrogenase, and O-linked N-acetylglucosamine transferase. In some instances, the biological devices also include a gene for enhanced green fluorescent protein. Methods for using the devices to diagnose or detect Alzheimer's disease and/or concussions are also provided herein.

Described herein are glucose sensors. The sensors are composed of host cells incorporating DNA devices specifically designed to produce fluorescence when the cells come into contact with glucose from a patient sample. Once the fluorescence has been quantified, it can be correlated with the amount of glucose present in the sample. Also described herein are extracts from the host cells that can sense and measure glucose levels in a patient. The devices and extracts disclosed herein are inexpensive but sensitive and accurate enough for use in both home and clinical testing situations. The devices and extracts disclosed herein are also useful for diagnosis of diabetes, pre-diabetes, or other diseases associated with elevated glucose levels.

Provided are lectenz molecules, which are mutated carbohydrate processing enzymes that are catalytically inactive and that have had their substrate affinity increased by at least 1.2 fold. Further provided are methods for making and methods of using such lectenz. Additional mutated proteins following the lectenz approach are further provided.

The present invention relates to methods for enhancing an adoptive cell transfer immunotherapy that targets an immunoglobulin light chain by administering a protein that has IgG cysteine protease or IgG endoglycosidase activity.